We are a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases.
Our two lead product candidates are in Phase 2 development. We are currently screening patients for the Phase 2b SPIRITUS trial for vapendavir, a potent, broad spectrum capsid inhibitor of enteroviruses, for the treatment of human rhinovirus (HRV) infected patients with moderate-to-severe asthma. Our second lead candidate, Laninamivir octanoate (LANI), is being developed for the treatment of influenza A and B infections, and has completed a global Phase 2 trial. In addition to these clinical development programs, we also have BTA-C585, a fusion inhibitor, in IND-enabling studies for the treatment of respiratory syncytial virus infections (RSV) in children and adults with cardiac and pulmonary disease and we plan to initiate a Phase 1 trial in mid-2015.
In addition to our research and development activities, we receive royalty revenue from two approved neuraminidase inhibitors: zanamivir, marketed worldwide as Relenza® by GlaxoSmithKline; and LANI, marketed in Japan as Inavir® by Daiichi-Sankyo.